In the second segment of the interview, Gilead’s Gelezinuas and SenGupta discuss the areas of unmet HIV therapy needs, cure research, and the benefits of a virtual conference.
In the first segment of an interview with Contagion®, during the AIDS20202 conference, Gilead’s Romas Gelezinuas, executive director, Biology and Devi SenGupta, MD, senior director, Clinical Research, Virology discuss the HIV investigational therapy, provide some insights in the mechanism of action, as well as what was learned in their study.
Gilead announced results from the study during International AIDS Society (IAS) AIDS 2020 Virtual Sessions.
Here in the second segment of the interview, Gilead’s Gelezinuas and SenGupta discuss the biggest areas of unmet HIV therapy needs, cure research, and the benefits and challenges of the virtual conference experience.
For example, in terms of HIV therapies, Gelezinuas talked about the three areas Gilead is involved in including prevention, treatment, and cure research. One of the areas he is most excited about is long-acting antiretroviral therapies.
To hear the conversation, click on the video below to get more insights.